These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 10917199)
1. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199 [TBL] [Abstract][Full Text] [Related]
2. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572 [TBL] [Abstract][Full Text] [Related]
3. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures. Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624 [TBL] [Abstract][Full Text] [Related]
5. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664 [TBL] [Abstract][Full Text] [Related]
6. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Schendel DJ; Gansbacher B Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887 [TBL] [Abstract][Full Text] [Related]
8. Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. Finke S; Trojaneck B; Möller P; Schadendorf D; Neubauer A; Huhn D; Schmidt-Wolf IG Cancer Gene Ther; 1997; 4(4):260-8. PubMed ID: 9253512 [TBL] [Abstract][Full Text] [Related]
9. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2. Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401 [TBL] [Abstract][Full Text] [Related]
10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
11. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome. Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677 [TBL] [Abstract][Full Text] [Related]
12. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780 [TBL] [Abstract][Full Text] [Related]
13. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
14. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824 [TBL] [Abstract][Full Text] [Related]
15. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951 [TBL] [Abstract][Full Text] [Related]
16. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065 [TBL] [Abstract][Full Text] [Related]
17. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
18. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994 [TBL] [Abstract][Full Text] [Related]
19. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]